Primary Care and Hepatology Provider Attitudes Towards Hepatitis C Treatment Candidacy and Adherence
AASLD LiverLearning®, Shari Rogal, 144647
Bridging the gap: Facilitating linkage to care for persons identified with chronic hepatitis C infections through a public health program
AASLD LiverLearning®, Arlene Sena, 144648
Impact of Pre-Existing Liver Disease on Treatment and Outcomes of Breast Cancer
AASLD LiverLearning®, Joseph Menzin, 144649
Effect of interferon free antiviral treatment on lipid metabolism, lipid oxidation and insulin-resistance in chronic hepatitis C patients with advanced liver disease
AASLD LiverLearning®, elisa biliotti, 144905
Hospital 30-day Readmission Rates in Patients with Decompensated Cirrhosis: A Nationwide Sample
AASLD LiverLearning®, George Cholankeril, 144650
Effect of pre-existing Hepatitis C NS3 Q80K variant in Genotype 1a and NS5A Y93H variant in Genotype 3 for interferon-free treatment combinations with direct antiviral agents (DAAs): Real-life experience from a multicenter study in Sweden and Norway
AASLD LiverLearning®, Johan Lennerstrand, 144906
'Othello Hypothesis' Involved in the Development of NS5A-RAVs in Patients with Genotype 1b HCV Infection
AASLD LiverLearning®, Yoshihito Uchida, 144907
High incidence of significant liver fibrosis among HBeAg-positive patients with low levels of ALT
AASLD LiverLearning®, Milan Sonneveld, 144663
Transient Elastography in Assessment of Liver Fibrosis in Children with Chronic Hepatitis B: PEG-B-ACTIVE Liver Elasticity Substudy
AASLD LiverLearning®, Vedran Pavlovic, 144664
Community-Based Strategies to Improve Testing and Linkage to Care for Foreign-Born Persons with Chronic Hepatitis B Virus Infection
AASLD LiverLearning®, Aaron Harris, 144665
Increase in 10-Year Framingham Cardiovascular Risk Following HCV Eradication with DAA-Based Therapy in HIV/HCV-Coinfected Patients
AASLD LiverLearning®, Teresa Aldámiz-Echevarría, 144921
Efficacy and safety of Telbivudine or Tenofovir use in second to third trimester preventing vertical transmission of hepatitis B virus in real-life practice
AASLD LiverLearning®, Jinfeng Liu, 144666
Ledipasvir/Sofosbuvir for 8 Weeks Results in High SVR Rates in Treatment-Naïve Patients with Chronic HCV Infection and HIV/HCV Co-Infection
AASLD LiverLearning®, Vasily Isakov, 144922
Incidence, predictors and outcome of ventilator associated pneumonia in critically ill cirrhotics admitted to a liver intensive unit.
AASLD LiverLearning®, AMRISH SAHNEY, 144923
Glucocorticoid Pulse Therapy and Hepatitis B Flares: A Retrospective Cohort Study
AASLD LiverLearning®, Sheng-Shun Yang, 144679
Progression of initially mild hepatic fibrosis in Chronic hepatitis B patients: a prospective repeat liver biopsy study
AASLD LiverLearning®, Xiao ling Chi, 144680
Patients with HIV-HBV coinfection are an underestimated reservoir for Hepatitis Delta Virus. An analysis of the ICONA cohort
AASLD LiverLearning®, Giovanni Gaeta, 144681
Does the presence of cirrhosis influence on the mortality rate in patients with acute on chronic liver failure?
AASLD LiverLearning®, Sombat Treeprasertsuk, 144937
Progression to liver-related complications in HIV/hepatitis B coinfected patients in the era of potent combination antiretroviral therapy (cART) is not increased compared to hepatitis B mono-infection
AASLD LiverLearning®, Faydra Lieveld, 144682
Long-term prognosis of patients who survived from acute-on-chronic liver failure based on KACLiF cohort
AASLD LiverLearning®, Eileen Yoon, 144938
Network Approach to unveil Molecular Pathways driving Cirrhosis progression to Acute-on-Chronic Liver Failure (ACLF)
AASLD LiverLearning®, Pere Gines, 144939
Preventing mother to child transmission of HBV in an ethnically diverse South London population: an effective multidisciplinary clinical pathway
AASLD LiverLearning®, Ivana Carey, 144695
Hepatitis B surface antigen (HBsAg) seroclearance, hepatocellular carcinoma (HCC) and liver-related death (LRD) risk among Alaska Native (AN) persons with indeterminate phase chronic hepatitis B virus infection (CHB) — Alaska, 2001-2014
AASLD LiverLearning®, Michael Bruce, 144696
Novel monitoring of hepatitis B reactivation based on ultra-high sensitive hepatitis B surface antigen assay
AASLD LiverLearning®, Noboru Shinkai, 144697
Monocyte HLA-DR expression, neutrophil oxidative burst capacity and cytokine analysis in patients with decompensated cirrhosis with and without acute-on-chronic liver failure (ACLF).
AASLD LiverLearning®, Ajay Duseja, 144953
MELD-Na and SBP predict mortality in Refractory Ascites
AASLD LiverLearning®, Sanaa Ayyoub, 144954
Alcohol-related acute on chronic liver failure- comparison of various prognostic scores in predicting outcome
AASLD LiverLearning®, . Shalimar, 144955
Subcirrhotic liver stiffness by transient elastography correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis
AASLD LiverLearning®, Mi Young Jeon, 144712
Male and hepatitis B infection are independent factors affecting patient’s compliance with surveillance of hepatocellular carcinoma
AASLD LiverLearning®, Satoshi Oeda, 144713
Patients with Refractory Ascites Treated with alfapump® System (AP) have Better Health-related Quality of Life (HRQL) as Compared to those Treated with Large Volume Paracentesis (LVP): Results of a Multicenter Randomized Controlled Study
AASLD LiverLearning®, Zobair Younossi, 144969
Epidemiological, clinical, biological and virological factors influencing the occurrence of hepatocellular carcinoma and validation of predictive scores in 317 HBV-related cirrhotic patients. Prospective study Cir-B nested in the ANRS CO12 CirVir cohort
AASLD LiverLearning®, Segolene Brichler, 144714
The Burden of Hepatorenal Syndrome among Commercially-Insured and Medicare Patients in the United States
AASLD LiverLearning®, Khurram Jamil, 144970
Treatment of refractory ascites with the automated low-flow ascites pump: analysis of the surveillance database
AASLD LiverLearning®, Guido Stirnimann, 144971
Profile of viral, biochemical and non-invasive fibrosis markers in a cohort of inactive European hepatitis B (HBV) carriers: 3 years follow-up of a prospective longitudinal study (ALBATROS Study)
AASLD LiverLearning®, Viola Knop, 144728
Expression profile alterations of lncRNAs on the molecular pathogenesis of hepatitis B*
AASLD LiverLearning®, Sunde Yilmaz Susluer, 144729
Rifaximin has no effect on hemodynamics in decompensated cirrhosis - A randomized, double blind, placebo controlled trial
AASLD LiverLearning®, Nina Kimer, 144985
Serum hepatitis B core-related antigen and surface antigen levels are correlated with hepatic fibrosis and inflammatory activity in treatment-naïve chronic hepatitis B patients
AASLD LiverLearning®, Tetsuya Hosaka, 144730
Rifaximin has limited effect on the inflammatory state and bacterial translocation in the patient with stable decompensated cirrhosis. Results from a randomized, placebo controlled trial.
AASLD LiverLearning®, Nina Kimer, 144986
Emricasan (IDN-6556) Orally for 6 Months in Patients with Cirrhosis and Elevated MELD Score Improves Liver Function
AASLD LiverLearning®, Catherine Frenette, 144987
Features of the metabolic syndrome are associated with lack of serum ALT normalization during therapy for chronic hepatitis B
AASLD LiverLearning®, Scott Fung, 144744
Low serum HBsAg level predicts HBsAg seroclearance and sustained response in chronic hepatitis B after stopping oral NUCs
AASLD LiverLearning®, Apinya Leerapun, 144745
The Multikinase-Inhibitor Regorafenib Improves Portal Hypertension In Presence And Absence Of Cirrhosis In Rats
AASLD LiverLearning®, Uschner Frank Erhard, 145001
The effects of non-alcoholic fatty liver disease on liver fibrosis in chronic hepatitis B patients on nucleoside analogue therapy: results from a matched-case control study.
AASLD LiverLearning®, Wai-Kay Seto, 144746
Antioxidant attenuates hyperdynamic circulation by mitigating mesenteric inflammation and nitric oxide production in cirrhotic rats
AASLD LiverLearning®, hongqun liu, 145002
Evaluation of Splenic Function in patients with Cirrhosis through observation of erythocytes with D.I.C. Microscopy.
AASLD LiverLearning®, Themistoklis Vasileiadis, 145003
TG1050, an HBV-targeted immunotherapeutics, efficiently decreases HBV viremia and antigenemia in a preclinical model; a meta-analysis and the determination of the involvement of CD4 and CD8 T cells
AASLD LiverLearning®, Roland Kratzer, 144760
Optimization of a Phase 2 Study Design in Chronic Hepatitis B (CHB) Patients Based on Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) from Phase 1 Studies Using Two Prodrugs of a Toll-like Receptor 7 (TLR7) Agonist
AASLD LiverLearning®, Joseph Grippo, 144761
A randomized, double-blind, double-dummy, controlled, multicenter study of entecavir maleate versus entecavir for treatment of Chinese chronic hepatitis B predominantly genotype B or C: results at week 144
AASLD LiverLearning®, Jinghang Xu, 144762
Risk of Renal Function Impairment Among Cancer Patients Treated With Tenofovir or Entecavir for HBV Prophylaxis During Chemotherapy
AASLD LiverLearning®, Yi-Hsiang Huang, 144776
Pharmacokinetics, Safety and Antiviral Activity of CMX157, a Novel Prodrug of Tenofovir, Administered as Ascending Multiple Doses to Healthy Volunteers and HBV-Infected Subjects
AASLD LiverLearning®, John Sullivan-Bolyai, 144778
Post-treatment dynamic changes of liver stiffness to predict first 2-year outcomes in HBV compensated cirrhosis
AASLD LiverLearning®, Hong You, 144779
The Effect of a 12-month Weight Loss Program on Non-alcoholic Fatty Liver Disease in Obese Patients
AASLD LiverLearning®, Anna Hefner, 144535
Limited Real-World Provider Prescription of 8 week LDV/SOF Regimen: A potential barrier in widespread treatment access
AASLD LiverLearning®, Chloe Gross, 144536
Introducing the Australasian Hepatology Association’s Consensus Guidelines for the Provision of Adherence Support to People with Hepatitis C taking Direct Acting Antivirals
AASLD LiverLearning®, Jacqueline Richmond, 144537
Minimal Changes in Urine Markers of Tubular Dysfunction in CHB Patients Receiving Tenofovir alafenamide (TAF) compared with Tenofovir Disoproxil Fumarate (TDF)
AASLD LiverLearning®, Young-Suk Lim, 144793
Nutritional Assessment Tools as Prognostic Tools in Cirrhotic Patients
AASLD LiverLearning®, Meri Koulentaki, 144538
Baseline Quantitative Hepatitis B Core Antibody Level strongly Predicts 240-week Treatment Response in HBeAg-positive Chronic Hepatitis B Patients Receiving Entecavir
AASLD LiverLearning®, Jinghang Xu, 144794
Elevated WFA+M2BP, ALT flare and HBs decline>1.0Log/ml during Peg IFN were predict drug free and HBs antigen clearance in sequential therapy with Peg-IFN alfa-2a on long-term nucleoside analog treated patients
AASLD LiverLearning®, Miwa Kawanaka, 144795
Regional and National understanding of IgG-related disease (IgG4-RD) in the UK- strategic implications in testing and case-finding
AASLD LiverLearning®, Marinos Pericleous, 144551
JKB-122 is Effective, Alone or in Combination with Prednisolone in Con A-induced Hepatitis, a Model for Autoimmune Hepatitis.
AASLD LiverLearning®, May Mei-Chi HSU, 144552
Frequency of CCR7-PD-1+ follicular helper T cell subset as a possible diagnostic marker of autoimmune hepatitis
AASLD LiverLearning®, Satoshi Yamagiwa, 144553
Treatment uptake for chronic hepatitis C in Australia following universal access to interferon-free treatments
AASLD LiverLearning®, Behzad Hajarizadeh, 144809
Vitamin D Deficiency is Associated with Progression to Cirrhosis and Decompensation in Patients with Autoimmune Hepatitis
AASLD LiverLearning®, Rahima Bhanji, 144554
Metabolic syndrome, hepatic steatosis and genotype 1b C virus compensated liver cirrhosis in the era of Direct Acting Antiviral therapy
AASLD LiverLearning®, Catalina Mihai, 144810
Preliminary Results from TOPAZ-III, A Phase 3b Study Evaluating the Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin in Naive or Experienced Adults in Brazil with HCV Genotype 1 Infection and Advanced Fibrosis/Cirrhosis
AASLD LiverLearning®, Mário Pessôa, 144811
High mobility group box-1 participates in the pathogenesis of liver fibrosis
AASLD LiverLearning®, Xiaodong GE, 144567
A novel murine model to deplete HSCs from normal liver with GFP-specific CD8+ T cells
AASLD LiverLearning®, Takuma Tsuchida, 144568
Bioinformatic Identification and Validation of C1QTNF2 as a Candidate Antifibrotic Molecule in Hepatic Stellate Cells
AASLD LiverLearning®, Daniel Hicks, 144569
Treatment of Patients with Hepatitis C Virus infection (Genotype 4) with Ledipasvir-Sofosbuvir in the liver transplant setting
AASLD LiverLearning®, Faisal Abaalkhail, 144825
25(OH) D3 alleviate liver NK cytotoxicity in early but not in late fibrosis model of Balb/c mice due to modulations in vitamin D receptor
AASLD LiverLearning®, Johnny Amer, 144570
Genotype 3 Infection In DAA Era: Preliminary Reports Of a Real Life Northern Italy Network For Viral Hepatitis
AASLD LiverLearning®, pasulo luisa, 144826
Effectiveness of Ledipasvir/Sofosbuvir±Ribavirin and Ombitasvir/Paritaprevir/Ritonavir+Dasabuvir±Ribavirin in 996 Genotype 1 HIV/HCV Coinfected Patients Treated in Routine Practice
AASLD LiverLearning®, Pamela Belperio, 144827
MMP9 is a potential mediator of TWEAK-Fn14 signaling in a rodent model of acute alcoholic steatohepatitis
AASLD LiverLearning®, Anna Mae Diehl, 144583
Loss of retinaldehyde dehydrogenase 1 enzymatic function attenuates liver fibrosis in a murine model of cirrhosis
AASLD LiverLearning®, Loretta Jophlin, 144584
Correlation of Cytoglobin Level in Stellate Cells with Promotion or Attenuation of Liver Fibrosis and Cancer in Mice
AASLD LiverLearning®, Thuy Le, 144585
Effectiveness of Sofosbuvir/Ledipasvir HCV Treatment Regimens in a Community Setting
AASLD LiverLearning®, T Craig Cheetham, 144841
Hepatic stellate cell Yes-associated protein 1 (Yap1) is necessary for liver regeneration
AASLD LiverLearning®, Anna Mae Diehl, 144586
Glyco-isomer of serum Mac-2-binding protein (M2BPGi) were dramatically decreased due to anti-viral therapy in chronic hepatitis C (CHC) patients
AASLD LiverLearning®, Mina Hamano, 144842
Use of Ledipasvir/Sofosbuvir (LDV/SOF) in Patients with Advanced Chronic Kidney Disease (eGFR ≤ 30ml/min): A Case Series
AASLD LiverLearning®, Thomas McQuaid, 144843
Screening of oesophagogastric varices in virus-related compensated advanced chronic liver disease: Baveno VI criteria and beyond
AASLD LiverLearning®, Roberta D Ambrosio, 144599
Management Of Refractory Variceal Bleed With Dannis-Ella Stent In Patients With Acute On Chronic Liver Failure
AASLD LiverLearning®, RAKHI MAIWALL, 144600
Vibration-Controlled Transient Elastography (VCTE) is Useful in Identifying Clinically Significant Portal Hypertension in Patients with NASH Cirrhosis
AASLD LiverLearning®, Raj Vuppalanchi, 144601
Treatment of Chronic Hepatitis C Genotype 4 -infected Patients with Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin: Real Life Data From Saudi Arabia
AASLD LiverLearning®, khalid alswat, 144857
MELD-HE score: a new model to predict risk of mortality in variceal bleeding
AASLD LiverLearning®, Marika Rudler, 144602
Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir and Ribavirin Pharmacokinetics in HCV-Infected Subjects with Chronic Kidney Disease Stage 4 (Severe Renal Impairment) or Stage 5 (End-Stage Renal Disease)
AASLD LiverLearning®, Diana Shuster, 144858
Efficacy and tolerability of IFN-free direct acting antivirals therapy (daclatasvir and asunaprevir) in chronic hemodialysis patients with chronic hepatitis C
AASLD LiverLearning®, Goki Suda, 144859
Hepatitis C Treatment in United States Prisons Prevents Transmission and is Cost-Saving for the Society
AASLD LiverLearning®, Jag Chhatwal, 144615
Ledipasvir/Sofosbuvir (LDV/SOF) treatment of naïve patients with mild chronic hepatitis C (CHC) genotype 1 (GT1) compared to patients with significant fibrosis: is it a cost-effective therapy?
AASLD LiverLearning®, Maria Buti, 144616
Hepatitis E infection in a large cohort of solid organ and stem cell recipients prior to transplantation
AASLD LiverLearning®, Jordi Llaneras Artigues, 144617
Safety and efficacy of regimens including direct acting antivirals (DAAs) in chronic hepatitis C (CHC) patients over the age of 70 years
AASLD LiverLearning®, Emmanouil Sinakos, 144873
Comparing the Inpatient Disease Burden of HCV and HIV Infections: Trends in Hospitalization, Cost of Care, and Length of Stay
AASLD LiverLearning®, George Cholankeril, 144618
Effectiveness of hcv antiviral treatment in patients with cirrhosis or advanced fibrosis and end-stage kidney disease on dialysis
AASLD LiverLearning®, Francesca Romana Ponziani, 144874
Difference of serum 4β-hydroxycholesterol level, a surrogate marker of CYP3A activity, among patients with chronic HCV infection
AASLD LiverLearning®, Tadashi Ikegami, 144875
Hospital re-admission predicts 5-year survival in patients with cirrhosis - A population-based study.
AASLD LiverLearning®, Jennifer Flemming, 144631
Outpatient primary care physician utilization before and after index hospitalization in patients with decompensated liver cirrhosis enrolled in a large national health insurance administrative database
AASLD LiverLearning®, Steven Scaglione, 144632
Differences in Hepatocellular Carcinoma Incidence and Survival Rates among Asian Mono-Ethnicities
AASLD LiverLearning®, George Cholankeril, 144633
Primary care based model using patient navigators highly successful in obtaining HCV medications for inner-city HCV-monoinfected patients
AASLD LiverLearning®, Wilma Toribio, 144889
Changes in liver biopsy training requirements to reflect competency-based medical education concepts
AASLD LiverLearning®, Oren Fix, 144634
chronic hepatitis c treatment with new generation direct-acting antivirals - real-life data from a portuguese center
AASLD LiverLearning®, LURDES SANTOS, 144890
Treatment Patterns Among Hepatitis C Virus Genotype 3 Patients in the United States
AASLD LiverLearning®, Lisa Rosenblatt, 144891